Liver transplantation

Current Opinion in Gastroenterology

Volumn 21, Issue 3, 2005, Pages 331-336

  Brown, Kimberly A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Liver transplantation; Living donor liver transplant; MELD

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; RIBAVIRIN;

ACCURACY; ANEMIA; BLOOD TOXICITY; CADAVER DONOR; CANCER SURVIVAL; CLINICAL TRIAL; HEPATITIS C; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MENTAL DISEASE; MODEL FOR END STAGE KIDNEY DISEASE SCORING SYSTEM; MORTALITY; ORGAN DONOR; POSTOPERATIVE COMPLICATION; PREDICTION; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

HUMANS; KIDNEY FAILURE, CHRONIC; LIVER FAILURE; LIVER TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT;

EID: 17844367843     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000159830.36793.2b     Document Type: Review

References (38)

1. Russo M, LaPointe-Rudow D, Kinkhabwala M, et al. Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. Am J Transplant 2004; 4:427-431.
2. Lo C, Fan S, Liu C, et al. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2004; 10:440-447.
3. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Ann Surg 2004; 240:451-461. One of the larger series evaluating the outcome of LDLT in patients with HCC.
4. Gondolesi G, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004; 239:142-149.
5. Lo C, Fan S, Liu C, et al. Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg 2004; 240:151-158.
6. Gondolesi G, Varotti G, Florman S, et al. Biliary complications in 96 consecutive right lobe living donor transplant recipients. Transplantation 2004; 77:1842-1848.
7. Renz J, Emond J, Yersiz H, et al. Split-liver transplantation in the united states: outcomes of a national survey. Ann Surg 2004; 239:172-181. Report of a national survey of 89 surgical teams regarding utility and outcomes of split liver transplantation.
8. Abt P, Desai N, Crawford M, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004; 239:87-92. The largest published results utilizing UNOS data of patient and graft survival following OLT with NHBD.
9. Desai N, Mange K, Crawford M, et al. Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation 2004; 77:99-106. Using a large cohort of patients from the UNOS database, the utility of MELD to predict post-transplant patient survival is evaluated.
10. Yao F, Saab S, Bass N, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004; 39:230-238.
11. Kremers W, Ijperen M, Kim W, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39:764-769. Using the UNOS database, the authors evaluate MELD as a predictor of pre- and post-transplant survival in UNOS status 1 patients and find that for fulminant hepatic failure (not due to acetaminophen), MELD appears to be predictive of outcome and may be useful in the future in prioritizing these patients.
12. Yao F, Bass N, Ascher N, Roberts J. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the model of end-stage liver disease (MELD) organ allocation policy. Liver Transpl 2004; 10:621-630.
13. Sharma P, Balan V, Hernandez J, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10:36-41.
14. Hayashi P, Trotter J, Forman L, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 2004; 10:42-48.
15. Trotter J, Osgood M. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004; 291:1871-1874. The authors review disparities in transplantation between small and large organ procurement organizations and find that a significantly smaller proportion of adult DDLT recipients in OPOs with small waiting lists receive transplants with MELD scores above 24 as compared with recipients in large OPOs.
16. Heuman D, Abou-assi S, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802-810.
17. Ruf A, Yantorno S, Descalzi V, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD along: A single center experience. Am J Transplant 2004; 4:438.
18. Khalili M, Lim J, Bass N, et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10:349-355.
19. Delgado-Borrego A, Casson D, Schoenfeld D, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77:703-710.
20. Velidedeoglu E, Mange K, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 2004; 77:1834-1842. In this study, 13,026 patients from the UNOS database were analyzed to identify factors associated with outcome in HCV+ and HCV- recipients.
21. Samuel D, Bizollon T, Feray C, et al. Interferon alfa 2b plus Ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650.
22. Abdelmalek M, Firpi R, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10:199-207.
23. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: an open-label series. Transplantation 2004; 77:190-194.
24. Ross A, Bhan A, Pascual M, et al. Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18:166-173.
25. Neff G, O'Brien C, Cirocco R, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004; 10:595-598.
26. Vlierberghe H, Troisi R, Colle I, et al. Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults. Transplantation 2004; 77:210-214.
27. Machicao V, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77:84-92.
28. Neumann U, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-231.
29. Russo M, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10:340-346. UNOS data were used in the largest series to date comparing outcomes for HCV+ recipients of LDLT vs. DDLT.
30. Forman L, Trotter J, Emond J. Living donor liver transplantation and hepatitis C. Liver Transpl 2004; 10:347-348.
31. Bozorgzadeh A, Jain A, Ryan C, et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004; 77:1066-1070.
32. Rodriguez-Luna H, Vargas H, Sharma P, et al. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci 2004; 49:38-41.
33. Garcia-Retortillo M, Forns X, Llovet J, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707.
34. Russo M, Shrestha R. Is severe recurrent hepatitis C more common after adult living donor liver transplantation? Hepatology 2004; 40:524-526.
35. Velidedeoglu E, Bloom R, Crawford M, et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004; 77:553-556. A retrospective study elucidating factors that are associated with the development of post-transplant chronic liver disease.
36. Sanchez E, Gonwa T, Levy M, et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 2004; 78:1048-1054. Using logistic regression analysis to identify factors predictive of renal failure following OLT, the authors devise a model which may be useful in predicting need for RRT following liver transplantation.
37. Paramesh A, Roayaie S, Doan Y, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004; 18:94-99.
38. Lam P, Yoshida A, Brown K, et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 2004; 49:1029-1035.